NSW Health Pathology

What NSW Health Pathology does

NSW Health Pathology is the public pathology and forensic & analytical science service of the State of New South Wales, operating as an administrative unit of the Health Administration Corporation under NSW Health. It is described on its own homepage as Australia's largest public pathology and forensic & analytical science service, employing more than 5,000 staff and running over 100,000 clinical and scientific investigations each day across a network of 150+ collection centres and hospital laboratories statewide. The service supports approximately 70% of medical decisions in the public system, indicating near-structural dependence of clinical decision-making on its output.

The organisation delivers services across three principal pillars. Clinical Pathology covers anatomical pathology, chemical pathology, haematology, immunology, microbiology, pre- and post-analytics, and transfusion medicine. Forensic & Analytical Science comprises forensic medicine, forensic and environmental toxicology, criminalistics, and a non-coronial autopsy service. Statewide Services extend the platform to public health pathology, genomics (rare diseases, cancer genomics, pathogen genomics, state-wide sequencing), point-of-care testing, the NSW Perinatal Postmortem Service (centred at Westmead, Randwick, and Newcastle), and the NSW Health Statewide Biobank. Digital services include an electronic reporting (eReporting) platform for clinicians — live for Hunter New England referrers as of 2026 — and an online Test Catalogue. Forward direction is set out in the published Strategic Plan 2026–2032.

The business model is publicly funded rather than commercial. NSW Health Pathology is financed through NSW Government appropriation and Medicare bulk-billing rebates, and it bulk bills for all Medicare-rebatable tests so patients face no out-of-pocket cost for the standard testing menu. It accepts all pathology request forms regardless of referring doctor, and its customer segments are NSW patients, healthcare professionals (GPs and clinicians) who order and consume results, and academic/clinical researchers who access biobanking, statewide research pricing, and ethics governance. As a government state entity, the organisation has no private shareholders, no venture or growth funding, and no disclosed revenue figure; its growth is governed by NSW Health budgetary cycles and the published strategic plan.

Name

NSW Health Pathology

Legal name

State of New South Wales (Health Administration Corporation – NSW Health Pathology)

Website

https://pathology.health.nsw.gov.au

Company type

Private

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

NSW Health Pathology is Australia's largest public pathology and forensic & analytical science service, operating 150+ collection centres across New South Wales with 5,000+ staff and conducting 100,000+ daily investigations for NSW patients, clinicians, and researchers under government funding.

Ownership category

akta.pro rank

Product category

Clinical Pathology Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

Keywords

• Clinical pathology services
• Forensic analytical science
• Medical diagnostic testing
• Public health pathology
• Genomics sequencing services

Headquarters

HQ city

Newcastle

HQ country

Australia

HQ region

Oceania

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Public Healthcare Funding: Publicly funded government service funded through NSW Health and Medicarerebate arrangements. The service bulk bills for Medicare rebatable tests, meaning patients are not out of pocket for these services.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

NSW Health Pathology is a publicly funded pathology and forensic & analytical science service that provides clinical diagnostic testing (anatomical pathology, chemical pathology, haematology, immunology, microbiology, transfusion), forensic medicine and analytical science services, statewide services (public health pathology, genomics, point-of-care testing, perinatal postmortem, biobanking), and digital tools such as eReporting and an online Test Catalogue. Services are bulk-billed for Medicare rebatable tests and accessible to all patients referred by healthcare professionals across more than 150 collection centres in NSW.

Product overview

NSW Health Pathology operates as a unified platform of pathology and forensic science services, combining Clinical Pathology (Anatomical Pathology, Chemical Pathology, Haematology, Immunology, Microbiology, Pre and Post-Analytics, Transfusion) with Forensic & Analytical Science (Forensic Medicine, Forensic and Environmental Toxicology, Criminalistics, Non-coronial Autopsy Service). Statewide Services including Public Health Pathology, Genomics, Point of Care Testing, NSW Perinatal Postmortem Service, and NSW Health Statewide Biobank extend reach across NSW. Digital services such as eReporting and a Test Catalogue support healthcare professionals. The organization performs over 100,000 clinical and scientific investigations daily across 150+ collection centres with more than 5,000 staff.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Pathology
• Forensic & Analytical Science
• Public Health Pathology

Quantifiable outcome

• Supports 70% of medical decisions with pathology testing
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Regional players

• Melbourne Pathology: Major Victorian private pathology provider serving hospitals and GPs. Comparable service mix (anatomical, chemical pathology, microbiology) and similar GP-referral driven model, but operating in Victoria rather than NSW.
• SA Pathology: South Australia's state public pathology service, structurally analogous to NHSHP (public-statewide provider, forensic science, biobanking). Useful benchmark for public-pathology operations in a different jurisdiction.
• PathWest Laboratory Medicine: Western Australia's public pathology provider, a direct functional twin of NHSHP within the WA health system. Comparable in mandate, forensic services mix and state-government funding model, but geographically non-competing.

Direct peers

• Sonic Healthcare: Australia's largest private pathology operator with extensive NSW coverage, providing directly comparable clinical pathology, anatomic pathology, genomics and laboratory services to GPs, hospitals and corporates. Most direct private-sector comparator to NHSHP.
• Australian Clinical Labs: ASX-listed private pathology operator with significant NSW footprint following the 2022 acquisition of Medlab Pathology. Comparable across clinical chemistry, microbiology, histology and genomics services.
• Healius (formerly Primary Health Care): Major Australian private pathology provider (Lumus, Laverty, QML, Dorevitch) operating collection networks across NSW. Competes head-to-head with NHSHP on GP referrals, turnaround time and bulk-billed testing.

Emerging players

• Garvan Institute of Medical Research: Sydney-based genomics and translational research institute with overlapping capability in rare-disease and cancer genomics. Partner/thematic peer to NHSHP's statewide genomic and biobanking services rather than a routine-pathology competitor.

Broad incumbents

• Quest Diagnostics: Large US-listed clinical laboratory network offering routine and esoteric testing, including anatomic, molecular and genomics diagnostics. Indirect global comparator at scale for NHSHP's clinical-pathology operations.
• NSW Health (parent system): Parent public health system under the Health Administration Corporation. Not a competitor but the dominant operating context, funder and customer for NHSHP, shaping demand, IT integration and strategic direction.

Others

• Public Pathology Australia: Peak body representing Australia's public pathology services, including NHSHP. Not a direct operator but an industry association that shapes funding advocacy, workforce policy and standards — closely connected to NHSHP's strategic positioning.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCGiBD8cD2lBy_7EEcdaENCw/videos
• Facebookfacebook.com/NSWHealthPathology
• LinkedInlinkedin.com/company/nsw-health-pathology

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NSW Health Pathology